An expert panel discusses recent advances in the treatment of Stage I-III NSCLC and their impact on clinical practice.
EP. 1: Multidisciplinary Care in Non-Small Cell Lung Cancer
A panel of experts introduce themselves and explain their approaches to multidisciplinary care in treating non-small cell lung cancer.
EP. 2: Patient Profile 1: A 57-Year-Old Woman Diagnosed With NSCLC
David Spigel, MD, presents a patient case of a 57-year-old woman with NSCLC, and Jaspal Singh, MD, MHS, discusses his approach to initial evaluation.
EP. 3: Workup and Molecular Testing for a Patient with NSCLC
David H. Harpole Jr, MD, a thoracic surgeon, details his workup approach and discussed molecular testing for patients who present with NSCLC.
EP. 4: Treatment Approach for Patients With Stage IB Disease
A panel of experts in the treatment of NSCLC discusses how they manage patients with stage IB disease.
EP. 5: Adjuvant Therapy in Early Stage NSCLC
David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.
EP. 6: Therapies Targeting Specific Molecular Alterations in NSCLC
A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.
EP. 7: Choosing Appropriate Patients for Surgical Resection in NSCLC
An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.
EP. 8: Patient Profile 2: Former Smoker Diagnosed With NSCLC
David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.
EP. 9: Treatment Approach for Patients With Stage II-IIIA NSCLC
Jaspal Singh, MD, MHS, shares insights on treatment strategies for patients with stage II-IIIA NSCLC.
EP. 10: Neoadjuvant Therapy and Other Emerging Therapies in Early Stage NSCLC
Experts discuss the role of neoadjuvant therapy and other emerging therapies in the treatment of early-stage NSCLC.
EP. 11: Unmet Needs and Future Perspectives in the NSCLC Treatment Landscape
Looking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber
HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging